Long-term Glycemic and Metabolic Profiles Observed During Imeglimin Therapy in Japanese Patients with Type 2 Diabetes Mellitus

Long-term effects of imeglimin on glycemic control, endogenous insulin secretion, and treatment intensity in patients with type 2 diabetes: a retrospective observational study - LITE study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000061139

Enrollment

Registered

2026-04-06

Start date

2024-10-28

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

type 2 diabetes

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with type 2 diabetes aged 20 or older who started imeglimin and continued treatment for 12 months or more.

Exclusion criteria

Exclusion criteria: Cases with type 1 diabetes, pregnant or breastfeeding women, patients with serious acute illnesses, and cases with insufficient follow-up data.

Design outcomes

Primary

Measure	Time frame
Change in HbA1c 12 months after starting imeglimin	—

Secondary

Measure	Time frame
Changes in glycated albumin (GA) Changes in the GA/HbA1c ratio Changes in the C-peptide index (CPI) Changes in the Medication effect score (MES)	—

Countries

Japan

Contacts

Public ContactYohei Fujita

Osaka General Medical Center Department of Diabetes and Endocrinology

fujita.yohei93@gmail.com0666921201

Outcome results